Project Number 2P50AG025688-11 Agency/Funding Organization NIA Funding Year 2015 View Full Project Details for DEFINING THE PROPERTIES OF PATHOGENIC A-BETA STRAINS IN AD Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category A. Molecular Pathogenesis and Physiology of Alzheimer's Disease and Alzheimer's Disease-related Dementias (AD/ADRDs) 1. Amyloid beta f. Amyloid beta Structure, Assembly, and Aggregation Category F. Research Resources 1. Alzheimer's Disease Centers Researcher and Organization Principal Investigator WALKER, LARY C Principal Investigator First Name LARY C Principal Investigator Last Name WALKER Awardee Organization EMORY UNIVERSITY Awardee State Georgia Contact PI Country United States Project Detail Funding Opportunity Announcement RFA-AG-15-002: Alzheimer's Disease Research Centers (P50) FY Overall Cost $201,534 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official PHELPS, CREIGHTON H. Related Resources Repository [NIAGADS] ADC1- Alzheimer Disease Center Dataset 1 [NIAGADS] ADC2- Alzheimer Disease Center Dataset 2 [NIAGADS] ADC3- Alzheimer Disease Center Dataset 3 [NIAGADS] ADGC African American Summary Statistics- Reitz et al. (2013) [NIAGADS] ADGC Neuropath Summary Stats and Phenotypes- Beecham et al. (2014) [NIAGADS] ADGC Summary Statistics- Naj et al. (2011) Emory University Alzheimer's Disease Research Center National Alzheimer's Coordinating Center (NACC) [AlzPED] Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice [AlzPED] 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease
